Panoramic Capital LLC Acquires Shares of 48,571 Pulse Biosciences, Inc. (NASDAQ:PLSE)

Panoramic Capital LLC acquired a new stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 48,571 shares of the company’s stock, valued at approximately $846,000. Panoramic Capital LLC owned approximately 0.08% of Pulse Biosciences as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its position in shares of Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company’s stock valued at $29,000 after acquiring an additional 838 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock valued at $2,598,000 after acquiring an additional 1,092 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock valued at $126,000 after acquiring an additional 2,220 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Pulse Biosciences by 27.1% during the 4th quarter. Wells Fargo & Company MN now owns 11,315 shares of the company’s stock valued at $197,000 after acquiring an additional 2,416 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Pulse Biosciences during the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Price Performance

PLSE stock opened at $16.84 on Wednesday. Pulse Biosciences, Inc. has a 12-month low of $6.66 and a 12-month high of $25.00. The stock’s 50 day simple moving average is $16.61 and its 200 day simple moving average is $18.01.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Monday, March 31st.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.